The role of hepatocyte TAZ in NASH and NASH-HCC.

被引：0
|
作者：
Wang, Xiaobo [1 ]
Schwabe, Robert [1 ]
Tabas, Ira [1 ]
机构：
[1] Columbia Univ, New York, NY USA
来源：
MOLECULAR CANCER RESEARCH | 2020年 / 18卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IA23
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [21] The role of regulatory T cells in NASH-mediated HCC development
    Yang, Ming
    Kimchi, Eric T.
    Staveley-O'Carroll, Kevin F.
    Li, Guangfu
    CANCER RESEARCH, 2023, 83 (07)
  • [22] Survival and HCC Recurrence After Liver Transplant due to NASH related HCC vs. Non-NASH Related HCC
    Fuentes, Anthony
    Sokolich, Julio
    Kumar, Ambuj
    Rogers, Ebonie
    Buggs, Jacentha
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 86 - 87
  • [23] Cholesterol crystallization within hepatocyte lipid droplets and its role in NASH
    Ioannou, George N.
    Subramanian, Savitha
    Chait, Alan
    Yeh, Matthew M.
    Haigh, W. G.
    Savard, Christopher
    HEPATOLOGY, 2015, 62 : 664A - 664A
  • [24] T cell drivers in NASH-HCC
    O'Leary, Karen
    NATURE REVIEWS CANCER, 2021, 21 (06) : 341 - 341
  • [25] Mitochondrial Dysfunction in the Transition from NASH to HCC
    Leveille, Melissa
    Estall, Jennifer L.
    METABOLITES, 2019, 9 (10)
  • [26] Is That Possible to Stop or Cease the NASH to Turn into HCC?
    Uygun A.
    Journal of Gastrointestinal Cancer, 2017, 48 (3) : 250 - 255
  • [27] Should Patients With NAFLD/NASH Be Surveyed for HCC?
    Reig, Maria
    Gambato, Martina
    Man, Nancy Kwan
    Roberts, John P.
    Victor, David
    Orci, Lorenzo A.
    Toso, Christian
    TRANSPLANTATION, 2019, 103 (01) : 39 - 44
  • [28] T cell drivers in NASH-HCC
    Karen O’Leary
    Nature Reviews Cancer, 2021, 21 : 341 - 341
  • [29] Lipogranulomas, neutrophils and the progression of NAFLD to NASH and HCC
    Mauricio, Joao C.
    Mahdi, Ahmed K.
    Lunec, John
    Patman, Gillian
    Whitehead, Anna
    Tiniakos, Dina
    Anstee, Quentin M.
    Oakley, Fiona
    Mann, Derek
    Wilson, Caroline
    Reeves, Helen
    HEPATOLOGY, 2017, 66 : 987A - 988A
  • [30] HCC and NASH: How strong is the clinical demonstration?
    Rosmorduc, O.
    Fartoux, L.
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2012, 36 (03) : 202 - 208
12345